News

  • 4 March 2020

    Immunocore Limited, a leading T cell receptor biotechnology company, and Pulse Infoframe Inc. (Pulse), with a platform healthie™ that supports patient registries, data aggregation and analytics, today announce that data collection for the first global patient registry in uveal melanoma (UM) has begun at Columbia University Irving Medical Center in New York. This effort is being co-led by Richard Carvajal, MD, from Columbia University Irving Medical Center and New York-Presbyterian Hospital, US, Joseph Sacco, MD, from the University of Liverpool, UK, and Anthony Joshua, MD, from The Kinghorn Cancer Centre, St Vincent’s Hospital Sydney, and the University of New South Wales, Australia. Ten additional centres across the US, UK and Australia are expected to open over the coming year.

  • 3 March 2020

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that setanaxib, the Company’s NOX1 and NOX4 inhibitor, was shown to significantly improve immunotherapy in multiple preclinical cancer models. Results from this preclinical study were published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research.

  • 2 March 2020

    Immunocore, a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease, today announced the completion of its Series B private financing round, generating more than $130 million.

  • 12 February 2020

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued United States Patent No. 10,548,889, which is expected to provide exclusivity of X4’s lead therapeutic candidate, mavorixafor (X4P-001), through 2038.

  • 6 February 2020

    Sonendo®, Inc., a dental technology company developing and commercializing products to save teeth through Sound Science®, announced today the appointment of Andrew Kirkpatrick as Chief Operating Officer.